These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795 [TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799 [TBL] [Abstract][Full Text] [Related]
5. Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma. Chang TS; Chen CL; Wu YC; Liu JJ; Kuo YC; Lee KF; Lin SY; Lin SE; Tung SY; Kuo LM; Tsai YH; Huang YH PLoS One; 2016; 11(2):e0149897. PubMed ID: 26919045 [TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861 [TBL] [Abstract][Full Text] [Related]
7. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment. You L; Liu C; Tang H; Liao Y; Fu S Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
9. Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells. Ji Y; Wang Z; Chen H; Zhang L; Zhuo F; Yang Q Cell Physiol Biochem; 2018; 47(1):39-53. PubMed ID: 29763915 [TBL] [Abstract][Full Text] [Related]
10. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671 [TBL] [Abstract][Full Text] [Related]
11. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734 [TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (review). Kasprzak A; Adamek A Int J Oncol; 2012 Dec; 41(6):1919-31. PubMed ID: 23076735 [TBL] [Abstract][Full Text] [Related]
13. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Shimizu M; Shirakami Y; Sakai H; Tatebe H; Nakagawa T; Hara Y; Weinstein IB; Moriwaki H Cancer Lett; 2008 Apr; 262(1):10-8. PubMed ID: 18164805 [TBL] [Abstract][Full Text] [Related]
14. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398 [TBL] [Abstract][Full Text] [Related]
15. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945 [TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. Hua H; Kong Q; Yin J; Zhang J; Jiang Y J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414 [TBL] [Abstract][Full Text] [Related]
17. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells. Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551 [TBL] [Abstract][Full Text] [Related]
18. The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway. E C; Li J; Shao D; Zhang D; Pan Y; Chen L; Zhang X Oncol Res; 2013; 21(2):103-10. PubMed ID: 24406046 [TBL] [Abstract][Full Text] [Related]
19. Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling. Grbčić P; Tomljanović I; Klobučar M; Kraljević Pavelić S; Lučin K; Sedić M Biochem Biophys Res Commun; 2017 Jun; 487(4):782-788. PubMed ID: 28433634 [TBL] [Abstract][Full Text] [Related]
20. Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine. Lin SL; Lin CY; Lee W; Teng CF; Shyu WC; Jeng LB Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]